Name | Ibalizumab |
---|
Description | Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research[1]. |
---|---|
Related Catalog | |
Target |
HIV-1 |
References |
[1]. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. |
No Any Chemical & Physical Properties |